Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
暂无分享,去创建一个
A. Zander | J. Szer | M. Horowitz | B. George | R. Gale | H. Khoury | J. Liesveld | Stephanie J. Lee | P. McCarthy | A. Keating | Tao Wang | D. Rizzieri | M. Arora | R. Champlin | R. Maziarz | M. Abecasis | E. Copelan | B. Bolwell | M. Litzow | Vikas Gupta | F. Cervantes | S. Giralt | D. Marks | E. Stadtmauer | J. Antin | O. Ilhan | J. Halter | G. Hale | H. Schouten | E. Olavarría | A. Woolfrey | M. Kukreja | M. Carabasi | Stephanie J. Lee
[1] C. Sawyers,et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. , 2008, Blood.
[2] T. Hughes,et al. Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia? , 2008, Nature Clinical Practice Oncology.
[3] J. Goldman. How I treat chronic myeloid leukemia in the imatinib era. , 2007, Blood.
[4] M. Horowitz,et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia , 2007, British journal of haematology.
[5] A. Gratwohl,et al. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerations , 2007, Leukemia.
[6] J. Radich,et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. , 2007, Blood.
[7] N. Schmitz,et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. , 2006, Blood.
[8] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[9] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[10] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[11] N. Kröger,et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study , 2006, European journal of haematology.
[12] R. Brand,et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.
[13] D. Marin,et al. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. , 2006, Haematologica.
[14] S. Iacobelli,et al. Design and Methods , 2022 .
[15] J. Vela-Ojeda,et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study , 2005, Bone Marrow Transplantation.
[16] J. Zaucha,et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.
[17] Lina Souan,et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. , 2004, Blood.
[18] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[19] N. Kröger,et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias , 2003, Leukemia.
[20] A. Nademanee,et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. , 2000, Blood.
[21] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[22] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[23] C Anasetti,et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.
[24] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Lancet.